Skip to main content


We are pleased to inform you about the successful completion of a multi-center Phase IIa study on 'Androgenetic Alopecia'. In this study, the medical team was able to absorb initial pandemic study postponements by scaling the number of study centers. In the end, we achieved excellent results with a total number of 210 randomized patients and a total of one drop-out.

We have summarized the particular challenges of this study, our approach to solving them, and the performance indicators in a case study. You can request this from our medical team.

Contact medical team

proderm is now part of SGS proderm is now part of SGS